Skip to content

Effects of Oxytocin on Social Behavior and Repetitive Behavior in Children with Autism.

A Course of Oxytocin To Improve Social Interaction and Repetitive Behaviors In Children With Autism Spectrum Disorders.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12611000061932
Enrollment
40
Registered
2011-01-17
Start date
2010-12-02
Completion date
2012-11-10
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Oxytocin is a natural hormone which plays a critical role in social behavior such as bonding, cooperativeness, trust, emotion recognition and face processing. Autism is a developmental disorder characterized by profound impairments in social behavior, communication and presence of repetitive behaviors. This study aims to assess the efficacy of oxytocin treatment in ameliorating social impairments in young children with autism. In particular, we aim to assess whether oxytocin treatment can improve the capacity for social interaction, face processing and reduce the occurrence of repetitive behaviors.

Interventions

Oxytocin nasal spray. Duration: 5 week treatment. First week, the dose will start at 3 International Units (IU) and increase by 3IU every 2 days. From the 7th day onwards, participants will receive 12IU for the remaining 4 weeks. The nasal spray will be delivered everyday, morning and night, one spray per nostril This is a crossover study, so after the first course of treatment, participants will have a 4 week washout period and then commence the alternative treatment. The alternative treatment

Oxytocin nasal spray. Duration: 5 week treatment. First week, the dose will start at 3 International Units (IU) and increase by 3IU every 2 days. From the 7th day onwards, participants will receive 12IU for the remaining 4 weeks. The nasal spray will be delivered everyday, morning and night, one spray per nostril This is a crossover study, so after the first course of treatment, participants will have a 4 week washout period and then commence the alternative treatment. The alternative treatment will follow the same dose escalation procedure as the first course of treatment.

Sponsors

University of Sydney
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
3 Years to 8 Years
Healthy volunteers
No

Inclusion criteria

Meet DSM-IV-TR criteria for ASD

Exclusion criteria

Not sensitive to preservatives (in particular E 216, E 218, and chlorobutanol hemihydrate)

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026